Your browser doesn't support javascript.
loading
Duration of atrial fibrillation persistence: Implications for recurrence risk after catheter ablation and efficacy of additional substrate ablation.
Matsunaga-Lee, Yasuharu; Inoue, Koichi; Tanaka, Nobuaki; Masuda, Masaharu; Watanabe, Tetsuya; Makino, Nobuhiko; Egami, Yasuyuki; Oka, Takafumi; Minamiguchi, Hitoshi; Miyoshi, Miwa; Okada, Masato; Kanda, Takashi; Matsuda, Yasuhiro; Kawasaki, Masato; Kawanami, Shodai; Ukita, Kohei; Kawamura, Akito; Yasumoto, Koji; Tsuda, Masaki; Okamoto, Naotaka; Yano, Masamichi; Nishino, Masami; Sunaga, Akihiro; Sotomi, Yohei; Dohi, Tomoharu; Nakatani, Daisaku; Hikoso, Shungo; Sakata, Yasushi.
Affiliation
  • Matsunaga-Lee Y; Division of Cardiology, Osaka Rosai Hospital, Sakai, Japan.
  • Inoue K; National Hospital Organization Osaka National Hospital, Osaka, Japan.
  • Tanaka N; Sakurabashi Watanabe Hospital, Osaka, Japan.
  • Masuda M; Kansai Rosai Hospital, Amagasaki, Japan.
  • Watanabe T; Osaka General Medical Center, Osaka, Japan.
  • Makino N; Osaka Police Hospital, Osaka, Japan.
  • Egami Y; Division of Cardiology, Osaka Rosai Hospital, Sakai, Japan.
  • Oka T; Osaka University Graduate School of Medicine, Suita, Japan.
  • Minamiguchi H; Osaka Police Hospital, Osaka, Japan.
  • Miyoshi M; Osaka Hospital, Japan Community Healthcare Organization, Osaka, Japan.
  • Okada M; Sakurabashi Watanabe Hospital, Osaka, Japan.
  • Kanda T; Osaka Police Hospital, Osaka, Japan.
  • Matsuda Y; Kansai Rosai Hospital, Amagasaki, Japan.
  • Kawasaki M; Osaka General Medical Center, Osaka, Japan.
  • Kawanami S; Division of Cardiology, Osaka Rosai Hospital, Sakai, Japan.
  • Ukita K; Division of Cardiology, Osaka Rosai Hospital, Sakai, Japan.
  • Kawamura A; Division of Cardiology, Osaka Rosai Hospital, Sakai, Japan.
  • Yasumoto K; Division of Cardiology, Osaka Rosai Hospital, Sakai, Japan.
  • Tsuda M; Division of Cardiology, Osaka Rosai Hospital, Sakai, Japan.
  • Okamoto N; Division of Cardiology, Osaka Rosai Hospital, Sakai, Japan.
  • Yano M; Division of Cardiology, Osaka Rosai Hospital, Sakai, Japan.
  • Nishino M; Division of Cardiology, Osaka Rosai Hospital, Sakai, Japan. Electronic address: mnishino@osakah.johas.go.jp.
  • Sunaga A; Osaka University Graduate School of Medicine, Suita, Japan.
  • Sotomi Y; Osaka University Graduate School of Medicine, Suita, Japan.
  • Dohi T; Osaka University Graduate School of Medicine, Suita, Japan.
  • Nakatani D; Osaka University Graduate School of Medicine, Suita, Japan.
  • Hikoso S; Osaka University Graduate School of Medicine, Suita, Japan.
  • Sakata Y; Osaka University Graduate School of Medicine, Suita, Japan.
Heart Rhythm ; 21(6): 733-740, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38307310
ABSTRACT

BACKGROUND:

The optimal duration of atrial fibrillation (AF) persistence for predicting poor outcomes after catheter ablation of long-standing AF (LsAF) and the best ablation strategy for these patients remain unclear.

OBJECTIVE:

We aimed to assess the impact of the duration of AF persistence on outcomes after catheter ablation of AF.

METHODS:

We analyzed the Efficacy of Pulmonary Vein Isolation Alone in Patients with Persistent Atrial Fibrillation (EARNEST-PVI) trial data comparing pulmonary vein isolation (PVI) alone (PVI-alone) with additional linear ablation or defragmentation (PVI-plus) in persistent AF (PerAF). Patients who received catheter ablation by contact force-sensing catheter were enrolled in the study. In patients with LsAF, the optimal cutoff duration of AF persistence was evaluated. With use of the threshold, patients with LsAF were divided into 2 groups and compared with PerAF <1 year for arrhythmia-free survival after a 3-month blanking period.

RESULTS:

The optimal cutoff duration was 2.4 years. Of 458 patients, arrhythmia-free survival rates for LsAF 1-2.4 years were comparable to those of PerAF (hazard ratio [HR], 1.01; 95% CI, 0.67-1.52). However, LsAF >2.4 years had a higher recurrence risk than PerAF (HR, 2.22; 95% CI, 1.42-3.47). In LsAF >2.4 years, the PVI-plus strategy showed advantages over the PVI-alone strategy (HR, 0.36; 95% CI, 0.14-0.89). However, the interaction effect between LsAF 1-2.4 years and LsAF >2.4 years did not reach statistical significance (P = .116).

CONCLUSION:

Whereas LsAF 1-2.4 years has similar outcomes to those of PerAF, LsAF >2.4 years was linked to higher arrhythmia recurrence risks. For LsAF >2.4 years, the PVI-plus strategy showed a potential to be superior to the PVI-alone strategy.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pulmonary Veins / Recurrence / Atrial Fibrillation / Catheter Ablation Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Heart Rhythm Year: 2024 Document type: Article Affiliation country: Japan

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pulmonary Veins / Recurrence / Atrial Fibrillation / Catheter Ablation Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Heart Rhythm Year: 2024 Document type: Article Affiliation country: Japan
...